May 20, 2016 / 11:11 AM / 3 years ago

Hikma wins dismissal of Takeda patent lawsuit over gout drug

A federal court has cleared the way for Hikma Pharmaceuticals Plc to continue selling a drug with the same active chemical as Takeda Pharmaceutical Co’s gout drug Colcrys, dismissing a patent lawsuit Takeda filed in an effort to keep the drug off the market.

U.S. District Judge Sue Robinson in Delaware ruled Wednesday that London-based Hikma does not induce doctors to infringe Japan-based Takeda’s patents by selling its drug Mitigare, because Mitigare is not indicated for the uses covered by Takeda’s patents.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below